Senate Bill 1049
115th Congress(2017-2018)
Opioid Addiction Risk Transparency Act
Introduced
Introduced in Senate on May 4, 2017
Origin Chamber
Senate
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
1049
Congress
115
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
No Senate votes have been held for this bill.
Summary
Opioid Addiction Risk Transparency Act
This bill amends the Federal Food, Drug, and Cosmetic Act to authorize the Food and Drug Administration to require a communication plan that is part of a medication's risk evaluation and mitigation strategy to include informing health care providers about the meaning of terms related to properties of the medication described in the labeling.May 4, 2017
05/04/2017
Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
05/04/2017
Introduced in Senate
Public Record
Record Updated
Jan 11, 2023 1:36:30 PM